Antibodies to the phospholipase A2 receptor 1 (PLA2R1) have been reported in 70% of
cases of idiopathic membranous nephropathy (IMN). The genetic susceptibility of IMN has …

The mainstay of treatment for high-risk primary membranous nephropathy (MN) is the cyclic
steroid-oral cyclophosphamide (cs-oral CYC) regimen (modified Ponticelli regimen)[1] …

Background: This study aimed to evaluate clinical features and prognosis and therapy
option of patients with different risk ranks based on antibody against the M-type …

Aim The phospholipase A2 receptor (PLA2R) is the major target antigen in idiopathic
membranous nephropathy (iMN). The aim of this prospective study was to determine the …

Background Membranous nephropathy (MN) is the leading cause of nephrotic syndrome in
adults. Anti-M-type phospholipase A2 receptor (anti-PLA2R) antibodies are found in most …

Background Identifying M-type phospholipase A 2 receptor (PLA 2 R) is a landmark
breakthrough for understanding adult idiopathic membranous nephropathy (iMN). However …

Background: Membranous Nephropathy (MN) is a rare autoimmune disease related to
PLA2R1 antibodies in 70% of cases. One third of patients enter in spontaneous remission …

Objective To discuss the relationship between serum anti-Phosphalipase A2 receptor
(PLA2R) antibodies and glomerular IgG4 subclass in patients with membranous …

Objectives: Autoantibodies against the M-type phospholipase A2 receptor 1 (anti-PLA2R1)
have been demonstrated to be very specific for idiopathic membranous nephropathy (MN) …

Background The Kidney Disease Improving Global Outcomes (KDIGO) 2021 guidelines
recommend Rituximab (RTX) as the first-line therapy and phospholipase A2 receptor …